Treatment of Sarcoidosis in Cardiac Sarcoidosis with Left Ventricular Ejection Fraction Below 50%

This protocol applies to patients with Sarcoidosis who have cardiac sarcoidosis and a left ventricular ejection fraction (LVEF) below 50%, indicating significant cardiac involvement that directly shapes the treatment approach.

Cardiac sarcoidosis with reduced LVEF represents a high-risk subset in which impaired left ventricular function — LVEF below 50% — is a central criterion guiding both the choice and duration of treatment. In patients who require ongoing therapy to maintain stable cardiac function, cytotoxic drugs are often considered as steroid-sparing agents.

Management in this setting is built around an oral corticosteroid-based strategy, with dose adjustment guided by cardiac response over time — the complete regimen, titration schedule, and decision algorithm are contained in the full protocol.

Many patients with significant cardiomyopathy and chronic sarcoidosis require long-term treatment to minimize progressive cardiac dysfunction.

The primary clinical target is stable or improved left ventricular ejection fraction. Survival in cardiac sarcoidosis correlates with left ventricular function and the presence of severe ventricular arrhythmias.